NVDL News Alert Novadel Pharma Inc (NVDL) 0.0089 10/01/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Novadel Pharma Inc (NVDL) 0.0089 $NVDL

NovaDel Announces the Sale of Its ZolpiMist(R) New Drug Application, License and Intellectual Property to Amherst Pharmaceuticals, LLC
Business Wire - Mon Sep 22, 7:30AM CDT
NovaDel Pharma Inc. (NVDL.PK) has sold its ZolpiMist(R) New Drug Application to Amherst Pharmaceuticals, LLC. The transaction also includes the NovaDel patents and trademarks covered by NovaDel's license agreement with ECR Pharmaceuticals Co., Inc. for US rights to ZolpiMist as well as the license agreement itself. Also included in the transaction are the international patents and trademarks for ZolpiMist.

NovaDel Announces Proposed Actions to Complete Liquidation of Assets and Cash Distribution to Shareholders
Business Wire - Wed Mar 26, 7:49AM CDT
As previously reported, NovaDel Pharma Inc. (NVDL.PK) is in the process of selling its assets in anticipation of liquidating the company and distributing its remaining cash to shareholders. Previously, Novadel has (i) sold its NovaMist(TM) patents and trademarks to SUDA LTD in exchange for cash and SUDA Common Stock and Options, (ii) sold its NitroMist(TM) patents and Trademarks and the NitroMist license to Akrimax, and (iii) entered into an agreement to sell the intellectual property and license to ECR for ZolpiMist(TM) for the assumption of the amount due to the FDA relating to ZolpiMist. This agreement is subject to the buyer obtaining financing. If financing is obtained, this sale should close by the end of April 2014.

Migraine - Pipeline Review, H2 2013
M2 - Wed Sep 04, 9:38AM CDT
Research and Markets (http://www.researchandmarkets.com/research/47gndq/migraine) has announced the addition of the "Migraine - Pipeline Review, H2 2013" report to their offering. 'Migraine - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Migraine, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Migraine. Scope - A snapshot of the global therapeutic scenario for Migraine. - A review of the Migraine products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Migraine pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Bristol-Myers Squibb Company Allergan, Inc. Amgen Inc. Questcor Pharmaceuticals, Inc. BioDelivery Sciences International, Inc. Merck & Co., Inc. Biofrontera AG Dr. Reddy's Laboratories Limited Teva Pharmaceutical Industries Limited Zosano Pharma, Inc. Capnia, Inc. Revance Therapeutics, Inc. IntelGenx Technologies Corp. NovaDel Pharma, Inc. Paladin Labs Inc. POZEN Inc. Choongwae Pharma Corp Orexo AB D-Pharm Ltd. Ache Laboratorios Farmaceuticos S/A Alder Biopharmaceuticals Inc. CoLucid Pharmaceuticals, Inc. and many more... For more information visit http://www.researchandmarkets.com/research/47gndq/migraine About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Erectile Dysfunction - Pipeline Review, H2 2013: An Overview of Pipeline Products for Erectile Dysfunction
M2 - Wed Sep 04, 9:38AM CDT
Research and Markets (http://www.researchandmarkets.com/research/l84sw4/erectile) has announced the addition of the "Erectile Dysfunction - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Erectile Dysfunction - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Erectile Dysfunction, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Erectile Dysfunction. Erectile Dysfunction - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A snapshot of the global therapeutic scenario for Erectile Dysfunction. - A review of the Erectile Dysfunction products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Erectile Dysfunction pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: - Acorda Therapeutics, Inc. - Chong Kun Dang Pharmaceutical - Dong-A Pharmaceutical Co., Ltd. - FCB-Pharmicell Co.,Ltd. - Fabre-Kramer Pharmaceuticals, Inc. - Futura Medical plc. - Global Health Ventures Inc. - IntelGenx Technologies Corp. - Medisyn Technologies, Inc. - NexMed, Inc. - NovaDel Pharma, Inc. - Palatin Technologies, Inc. - Sanofi-Aventis - Senetek PLC - VIVUS, Inc. - Yuhan Corporation For more information visit http://www.researchandmarkets.com/research/l84sw4/erectile About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

NovaDel Pharma Inc announces sale of assets to Suda Ltd
M2 - Wed Aug 14, 7:47AM CDT
Specialist pharmaceutical company NovaDel Pharma Inc (OTC Pink:NVDL) reported on Tuesday the completion of the divestiture of substantially all of its assets to Suda Ltd.

NovaDel Announces Completion of the Sale of Substantially All Assets to Suda Ltd.
Business Wire - Tue Aug 13, 3:01PM CDT
NovaDel Pharma Inc. ("NovaDel" or "the Company" (OTC Pink: NVDL) announced today the completion of the sale of substantially all of the Company's assets to Suda Ltd. (the "Suda Transaction" .

Sleep Disorders - Pipeline Review, H2 2013 Features Players such as Ono Pharmaceutical Co., Ltd and
M2 - Thu Aug 08, 11:52AM CDT
Research and Markets (http://www.researchandmarkets.com/research/xc32xz/sleep_disorders) has announced the addition of the "Sleep Disorders - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Sleep Disorders - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Sleep Disorders, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Sleep Disorders. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A snapshot of the global therapeutic scenario for Sleep Disorders. - A review of the Sleep Disorders products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Sleep Disorders pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: - Athersys, Inc. - CoLucid Pharmaceuticals, Inc. - Ferrer Internacional S.A. - Neurim Pharmaceuticals (1991) Ltd. - NovaDel Pharma, Inc. - Ono Pharmaceutical Co., Ltd. - Teva Pharmaceutical Industries Limited For more information visit http://www.researchandmarkets.com/research/xc..._disorders About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Suda Ltd to acquire assets of NovaDel Pharma Inc
M2 - Mon Jul 22, 3:05AM CDT
Specialty pharmaceutical company NovaDel Pharma Inc (OTC Pink: NVDL) announced on Friday the approval by its stockholders, during the Special Meeting of Stockholders held on 19 July 2013, of the sale of substantially all of the company's assets to Suda Ltd.

NovaDel Announces Stockholder Approval of Sale of Substantially All Assets to Suda Ltd.
Business Wire - Fri Jul 19, 4:55PM CDT
NovaDel Pharma Inc. ("NovaDel" or the "Company" (OTC Pink: NVDL) announced today that, during the Special Meeting of the Company's Stockholders held on July 19, 2013, its stockholders approved the sale of substantially all of the Company's assets to Suda Ltd. (the "Suda Transaction" . However, approval for the liquidation and dissolution of the Company was not received by the requisite number of stockholders and therefore the proposal did not pass. Therefore, NovaDel will not file for dissolution at this time and will continue to pursue alternative avenues in order to maximize stockholder value.

NovaDel Announces Adjournment of Special Stockholder Meeting
Business Wire - Thu Jun 27, 10:32AM CDT
--NovaDel Stockholders Are Urged To Vote FOR the Proposals

Male Sexual Dysfunction - Global Pipeline Review, H1 2013
M2 - Fri Jun 21, 5:15AM CDT
Research and Markets (http://www.researchandmarkets.com/research/44glgt/male_sexual) has announced the addition of the "Male Sexual Dysfunction - Pipeline Review, H1 2013" report to their offering. 'Male Sexual Dysfunction - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Male Sexual Dysfunction, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Male Sexual Dysfunction. Scope - A snapshot of the global therapeutic scenario for Male Sexual Dysfunction. - A review of the Male Sexual Dysfunction products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on

NovaDel Pharma Inc plans to divest NovaMist technology and certain other assets
M2 - Tue Apr 09, 10:44AM CDT
Pharmaceutical company NovaDel Pharma Inc (OTC Markets:NVDL.PK) stated on Monday that it has entered into a definitive agreement to sell its NovaMist technology and certain other assets.

NovaDel Announces the Signing of a Definitive Agreement to Sell its NovaMist(TM) Technology and Certain Other Assets
Business Wire - Mon Apr 08, 7:30AM CDT
NovaDel Pharma Inc. (NVDL.PK) has signed a definitive agreement to sell its NovaMist(TM) technology and certain other assets to SUDA LTD, an Australian publicly held pharmaceutical company.

NovaDel Pharma Inc's net loss narrows to USD471,000 in 2012
M2 - Thu Mar 28, 8:33AM CDT
Pharmaceutical company NovaDel Pharma Inc (OTC Markets:NVDL) reported on Wednesday its net loss of USD1.2m (USD0.01 per share) for the 12 months ended 31 December 2012.

Sleep Disorders - Pipeline Review, H1 2013
M2 - Thu Mar 28, 5:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/mwv5bk/sleep_disorders) has announced the addition of the "Sleep Disorders - Pipeline Review, H1 2013" report to their offering. Global Markets Direct's, 'Sleep Disorders - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Sleep Disorders, complete with latest updates, and special features on late-stage and discontinued projects.It also reviews key players involved in the therapeutic development for Sleep Disorders. Scope - A snapshot of the global therapeutic scenario for Sleep Disorders. - A review of the Sleep Disorders products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of mono

NovaDel Reports Unaudited Financial Results for the Twelve Months Ended December 31, 2012
Business Wire - Wed Mar 27, 7:00AM CDT
NovaDel Pharma Inc. (NVDL.PK) reported unaudited financial results for the twelve months ended December 31, 2012.

Anxiety Disorders - Pipeline Review, H2 2012
M2 - Thu Jan 17, 3:50AM CST
Research and Markets (http://www.researchandmarkets.com/research/nw7hxn/anxiety_disorders) has announced the addition of Global Markets Direct's new report "Anxiety Disorders - Pipeline Review, H2 2012" to their offering. This report provides information on the therapeutic development for Anxiety Disorders, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Anxiety Disorders. Anxiety Disorders - Pipeline Review, Half Year is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Scope - A snapshot of the global therapeutic scenario for Anxiety Disorders. - A review of the Anxiety Disorders products under development by companies and universities/research institutes base

NovaDel Announces Preliminary Agreement to Sell its NovaMist(TM) Technology
Business Wire - Wed Dec 26, 3:00PM CST
NovaDel Pharma Inc. (NVDL.PK) has signed a preliminary agreement to sell its NovaMist(TM) technology to SUDA LTD, an Australian publicly held pharmaceutical company.




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Paris Baguette Expands U.S. Presence with New Georgia Café

Updated Category News Views 163

Café Culture Meets Expansion Chase You ever sip a cup of coffee and hear the rustle of opportunity in the steam? That's what's brewing at Paris Baguette with their new opening in Peachtree Corners, Georgia. This isn't just another café setting up shop; it's part of a larger scheme—expanding their sweet slice of the global market pie. Paris Baguette's Georgia Gamble...

Continue Reading
EUBG Faces Tough Third Quarter Amid Challenges

Updated Category News Views 193

What's Happening with EUBG? Entrepreneur Universe Bright Group, better known in the markets as EUBG, is navigating some choppy waters if their recent financial numbers are anything to go by. You'd think companies boasting a digital-focused strategy would be printing money in today's tech-driven world, but EUBG's third quarter of 2026 has a different story to tell. The...

Continue Reading
Arbor Realty Trust Hit with Securities Fraud Lawsuit

Updated Category News Views 131

Snafu at Arbor Realty: Investors Rethink Strategies You know what puts a bee in my bonnet these days? Misleading statements from companies like Arbor Realty Trust, Inc. (NYSE: ABR). The news breaks that Arbor's got itself neck-deep in a class action lawsuit, courtesy of the sharp folks over at Schall, Brown & Schwartz LLP. Now, this ain't your average financial hiccup....

Continue Reading
Biotech Hit or Miss: Trials and Tribulations

Updated Category News Views 104

Biotech's Roller Coaster: Triumphs and Setbacks Ah, the biotech sector—it's a bit like jumping on a bull, ain't it? You barely hang on when the beast bucks. Monday's market action was downright wild. The S&P 500 didn't have a party, tumbling 1.92%, and the Nasdaq wasn't any friendlier, plummeting 2.49%. Yet, inside this storm, we see some biotech names either catching...

Continue Reading
Exploring Creation: A Fresh Look at Genesis

Updated Category News Views 88

Opening Up Genesis in a New Light Hey, if you’re like most folks, you’ve probably heard Genesis framed as the battleground for science versus religion debates, right? Enter into this mix a fresh take with Robert E. Franzen’s new book, The Narration of Creation. This book asks you to overlook those grand philosophical fights and instead focus on the narrative itself....

Continue Reading
NVCA Refreshes Key Venture Legal Documents for 2026

Updated Category News Views 115

Keeping Pace with Evolving Venture Norms Change never lets up in the fast-paced world of venture capital, does it? Just when you think you've got the rules figured out, the game shifts. This time, it's the National Venture Capital Association (NVCA) shaking things up. They've given a facelift to seven of their model legal documents, a move that reshapes the legal...

Continue Reading
Nasdaq Tumbles: AI Hardware Pulls Markets Down

Updated Category News Views 95

Wall Street's Slide Fueled by AI Nerves The markets got a real jolt on Monday, sending Nasdaq down 2.5% thanks to a sharp dip in AI hardware stocks. Tech tickers tied to artificial intelligence were at the core of a sell-off, knocking the S&P 500 down 1.92% alongside it. Investors are on edge, and it’s not just the weather—it's a real shake-up driven by policy moves...

Continue Reading
Tigo Energy Faces Lawsuit: Key Details for Investors

Updated Category News Views 123

Tigo Energy Inc.'s Troubles: A Stock Drop and Legal Woes You see, not every day do you wake up to find your investment taking a nose dive by 36.76%. But that’s exactly what happened to Tigo Energy, Inc. (NASDAQ: TYGO) after some shaky announcements. A Rollercoaster for Investors On August 4, 2026, Tigo hit investors with a one-two punch: revised financial outlook and...

Continue Reading
Sharon Stuart's Quest for Her Hidden Origins

Updated Category News Views 123

Delving Into Identity: A Personal Odyssey In a world where everyone seems to be searching for something, Sharon Stuart's quest is etched with the raw need to uncover her real origins. Abandoned as a newborn in the gritty streets of Oakland, she grew up grappling with looming questions about what made her who she is. Her journey is captured in her memoir, "Existing Without...

Continue Reading
A Teen's Opera Encounter Inspires Decades of Passion

Updated Category News Views 94

Unraveling a Lifelong Opera Obsession Back in the dog-eared days of 1970, a teenager waltzed into the Metropolitan Opera and stumbled onto a passion that'd pulse alongside him for over half a century. Now, David E. Lapin rolls out his personal chronicle, 'A Sound Obsession: Fifty-Five Years of Opera at the Met.' Folks, we’re diving into a cultural tapestry that’s...

Continue Reading

Top 5 Most Recently Viewed Articles

APh ePower's 2025 R&D Achievement: Transforming Elevator Energy

Updated Category News Views 178

APh ePower's Remarkable Innovation Award The leader in aluminum battery technology is not only setting standards for efficiency but is also making strides in sustainability. Recently, APh ePower was honored with the prestigious 2025 R&D 100 Award for its groundbreaking Elevator Regenerative Power System (ERPS). This award highlights the company's efforts in redefining...

Continue Reading
Butterfly Completes $300 Million Loan for Milk Specialties Growth

Updated Category News Views 349

Butterfly Completes Major Dividend Recapitalization Butterfly, a well-known private equity firm based in Los Angeles, has made a significant move in the food industry by securing a substantial $300 million second lien term loan facility. This funding is intended to support Milk Specialties Global, an important portfolio company recognized for its innovative methods in...

Continue Reading
Rezolve Ai Enhances BRAiN Assistant for Optimal User Engagement

Updated Category News Views 73

Rezolve Ai Introduces Key Updates to BRAiN Assistant Rezolve Ai (Nasdaq: RZLV) has made a bold move in the realm of AI technology with a substantial update to its BRAiN Assistant. This upgraded platform is designed to significantly enhance user experience and response accuracy, reinforcing the company's dedication to harnessing innovative technology for superior AI-driven...

Continue Reading
Minesto Teams Up to Unlock Tidal Power in Maldives

Updated Category News Views 270

The world of ocean energy just got a jolt from an unlikely corner. Minesto, the ocean energy whiz, and Morteza Capital, a savvy investment force entrenched in the Maldives, are shaking hands to usher tidal energy into this paradise. Tidal Waves Meet Tourism When you're talking about the Maldives, you're talking about two main things: pristine tropical getaways and a whole...

Continue Reading
Promising New Insights on Dual Masked T-Cell Engagers from Vir

Updated Category News Views 216

Encouraging Developments in Cancer Treatment by Vir Biotechnology Vir Biotechnology, Inc. (NASDAQ: VIR) has recently shared commendable initial Phase 1 data regarding their innovative dual-masked T-cell engagers (TCEs): VIR-5818 and VIR-5500. These breakthroughs target challenging forms of cancer, notably HER2-expressing solid tumors and metastatic castration-resistant...

Continue Reading